» Articles » PMID: 24335700

Heat-shock Protein Peptide Complex-96 Vaccination for Recurrent Glioblastoma: a Phase II, Single-arm Trial

Abstract

Background: Outcomes for patients with recurrent glioblastoma multiforme (GBM) are poor and may be improved by immunotherapy. We investigated the safety and efficacy of an autologous heat-shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent GBM.

Methods: In this open-label, single-arm, phase II study, adult patients with surgically resectable recurrent GBM were given vaccine after gross total resection. The primary endpoint was overall survival at 6 months. Secondary endpoints included overall survival, progression-free survival, safety, and immune profiling. Outcome analyses were performed in the intention-to-treat and efficacy populations.

Results: Between October 3, 2007 and October 24, 2011, 41 patients underwent gross total resection of recurrent GBM and received a median of 6 doses of HSPPC-96 vaccine. Following treatment, 90.2% of patients were alive at 6 months (95% confidence interval [CI]: 75.9-96.8) and 29.3% were alive at 12 months (95% CI: 16.6-45.7). Median overall survival was 42.6 weeks (95% CI: 34.7-50.5). Twenty-seven (66%) patients were lymphopenic prior to therapy, and patients with lymphocyte counts below the cohort median demonstrated decreased overall survival (hazard ratio: 4.0; 95% CI: 1.4-11.8; P = .012). There were no treatment-related deaths. There were 37 serious (grades 3-5) adverse events reported, with 17 attributable to surgical resection and a single grade 3 constitutional event related to the vaccine.

Conclusion: The HSPPC-96 vaccine is safe and warrants further study of efficacy for the treatment of recurrent GBM. Significant pretreatment lymphopenia may impact the outcomes of immunotherapy and deserves additional investigation.

Citing Articles

Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.

De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P J Neurooncol. 2025; .

PMID: 40080248 DOI: 10.1007/s11060-025-04989-z.


A new weapon: the application of tumor vaccines based on extracellular exosomal heat shock proteins in immunotherapy.

Yi K, Sun C, Yuan Y, Luo Z, Luo H, Xie Y Front Immunol. 2025; 16:1510650.

PMID: 39911383 PMC: 11794256. DOI: 10.3389/fimmu.2025.1510650.


Bibliometric analysis of the top 100 most cited articles on the immunotherapy for glioblastoma.

He C, Xiong P, Zeng C, Qiu X, Long T, Song H Childs Nerv Syst. 2024; 41(1):33.

PMID: 39633087 DOI: 10.1007/s00381-024-06693-1.


Multifaceted impact of HIV inhibitor dapivirine on triple negative breast cancer cells reveals potential entities as targets for novel therapy.

Patil K, Johnston E, Novack J, Wallace G, Lin M, Pai S Sci Rep. 2024; 14(1):30103.

PMID: 39627279 PMC: 11615302. DOI: 10.1038/s41598-024-79789-y.


Immunotherapy for glioblastoma: current state, challenges, and future perspectives.

Liu Y, Zhou F, Ali H, Lathia J, Chen P Cell Mol Immunol. 2024; 21(12):1354-1375.

PMID: 39406966 PMC: 11607068. DOI: 10.1038/s41423-024-01226-x.


References
1.
Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

2.
Perry J, Belanger K, Mason W, Fulton D, Kavan P, Easaw J . Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010; 28(12):2051-7. DOI: 10.1200/JCO.2009.26.5520. View

3.
Learn C, Fecci P, Schmittling R, Xie W, Karikari I, Mitchell D . Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006; 12(24):7306-15. DOI: 10.1158/1078-0432.CCR-06-1727. View

4.
Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K . Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol. 2010; 29(3):337-44. DOI: 10.1200/JCO.2010.29.7499. View

5.
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G . Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010; 12(8):871-81. PMC: 2940677. DOI: 10.1093/neuonc/nop054. View